BiotechFinances
ASTHMA: Ludocare (Lyon) – First digital therapy on track for reimbursement

ASTHMA: Ludocare (Lyon) – First digital therapy on track for reimbursement

May 14, 2026

"a mobile application and a companion health robot and 42% fewer severe asthma attacks in children aged 7 to 11", ALEXANDRA DE LA FONTAINE, CEO of Ludocare

Translated by artificial intelligence from the original French version. Learn more

A major first for Ludocare. The young Lyon-based startup became, in early April, the first to obtain a favorable opinion from the Haute Autorité de santé (HAS) with a view to reimbursement for a digital therapy in France. The use of the device « JOE », composed of a mobile application and a companion health robot, showed a 42% reduction in severe asthma attacks in children aged 7 to 11 with persistent asthma, in a national clinical study lasting more than two years. “These complications are responsible for more than 46,000 hospitalizations per year among children under 15, which can lead to lung damage, school absenteeism and...

Written byPierre HavezBiotechFinances

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.

Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consectetur, adipisci velit.

At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt.

Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum.

Subscribe

Read more...

This is a standard plan article, subscribe to access the full content